Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | YAP1 | P46937 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13913655 | 0.87 | KDM4E (0.60) | GPR119KDM4EPKMFAAHOPRK1 | |
| SCHEMBL4147236 | 0.87 | SLC2A1 (0.56) | GPR119TGFBR1 | |
| SCHEMBL4139485 | 0.85 | MGLL (0.53) | GPR119KDM4EPKMFAAHSTS | |
| SCHEMBL3358948 | 0.83 | KDM4E (0.59) | GPR119KDM4EPKMFAAHSTS | |
| SCHEMBL30812306 | 0.83 | SIGMAR1 (0.54) | KDM1A | |
| SCHEMBL27980806 | 0.83 | SIGMAR1 (0.54) | KDM1A | |
| SCHEMBL15498207 | 0.83 | GPR119 (0.45) | GPR119KDM4EPKMFAAHOPRK1 | |
| SCHEMBL27379752 | 0.81 | GPR119 (0.50) | GPR119KDM4EPKMTGFBR1STS | |
| SCHEMBL22839895 | 0.81 | GPR119 (0.47) | GPR119KDM4EPKMTGFBR1STS | |
| SCHEMBL4325703 | 0.81 | GPR119 (0.58) | GPR119KDM4EPKMFAAHKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054956-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |